Zoetis (NYSE: ZTS) stock declined by 0.41% following a significant reduction in Choreo LLC's stake by 32.7%, amidst mixed ratings and price target adjustments from analysts.

Zoetis (NYSE: ZTS) stock declined by 0

Zoetis Inc. (NYSE: ZTS) stock rose 1.49% amid ongoing concerns about competitive pressures in the animal health market and Aristotle Atlantic Partners' decision to sell their stake due to perceived overvaluation and better opportunities elsewhere; however, its revenue showed slight growth recently, which may have contributed to the uptick in stock price.

Zoetis Inc

Zoetis Inc. (ZTS) stock fell by 0.83% following a downgrade from analysts at Leerink Partners who reduced their rating from "outperform" to "market perform" and cut the price target from $180.00 to $155.00, indicating a cautious sentiment in the market regarding the stock's future performance.

Zoetis Inc. (ZTS) stock fell by 2.42% due to analysts lowering their price targets and ratings for the stock, with UBS Group assigning a neutral rating and Stifel Nicolaus changing their recommendation from buy to hold, indicating a shift in market sentiment.

Zoetis Inc. (NYSE: ZTS) experienced a decline of 1.34% in its stock price, largely attributed to analysts downgrading their ratings and price targets for the stock.

Zoetis Inc. (ZTS) stock rose by 0.06% due to a combination of positive earnings results that surpassed analyst estimates, an increase in institutional investment activity, and favorable analyst ratings, despite some recent share sales by company executives.

Zoetis (ZTS) stock fell by -0.14% due to general market fluctuations and specific performance variances relative to competitor stocks, although the article primarily contrasts American Well and Decision Diagnostics rather than focusing on Zoetis.

Zoetis (ZTS) stock fell by -0

Zoetis (ZTS) stock increased by 0.24% likely due to a combination of positive sentiment from institutional investors, recent upgrades from various brokerages, and a strong earnings report that exceeded analysts' expectations.

Zoetis (ZTS) stock increased by 0

Zoetis Inc. (ZTS) stock rose 0.24% last night, attributed to a mix of institutional investment changes, analyst upgrades, and positive quarterly earnings exceeding expectations.

Zoetis Inc. (ZTS) saw a 0.34% decline in its stock due to a downgrade by Stifel analyst Jonathan Block, who changed the rating from "Buy" to "Hold" and lowered the price target from $165 to $160.

Zoetis Inc. (ZTS) stock fell 0.34% following a downgrade by Stifel analyst Jonathan Block, who expressed concerns that the company's revenue growth may not meet Wall Street expectations due to increased competition and slower growth in key market segments.

Zoetis (ZTS) stock rose by 1.36% despite a downgrade from Stifel Nicolaus to a "hold" rating, mainly due to mixed analyst reports where some increased their price targets, suggesting potential for growth, and the company's strong recent earnings performance that exceeded expectations.

Zoetis (ZTS) stock rose by 1

The article discusses Zoetis Inc. (ZTS) stock, which rose 1.36% due to a favorable earnings report, positive price target adjustments from several analysts, and significant institutional investment, despite some insider selling and mixed ratings. 

Zoetis's stock increase is attributed to better-than-expected quarterly earnings, with reports of earnings per share exceeding estimates and an encouraging revenue outlook, along with strong institutional buying interest.

The article discusses Zoetis Inc

Zoetis Inc. (NYSE:ZTS) shares fell by 4.09%, attributed to a combination of insider selling, analyst downgrades on price targets, and a broader market response to recent earnings results.

Zoetis (ZTS) stock fell by 4.09% due to changes in institutional holdings, with Trust Point Inc. reducing its position by 30%, alongside newly lowered price targets from several brokerages, despite the company having reported better-than-expected earnings.

Zoetis (ZTS) stock fell by 4

Zoetis Inc. (NYSE: ZTS) stock fell by 1.65%, attributed primarily to recent adjustments in price targets by analysts, such as UBS Group lowering its target from $189.00 to $170.00, combined with insider selling activities and overall market fluctuations.

Zoetis Inc. (NYSE:ZTS) stock fell by -1.65% amid a backdrop of mixed investor activity and various institutional modifications of their holdings, despite the company reporting better-than-expected earnings and an increase in revenue. The decline could be attributed to recent analyst rating adjustments and insider selling, which may have influenced investor sentiment.

Zoetis Inc. (NYSE: ZTS) stock has seen a slight increase of 0.03% due to a strong average recommendation of "Buy" from research analysts and a positive outlook on its earnings, including a quarterly earnings report that surpassed expectations.

Zoetis (ZTS) stock declined by 0.46% recently despite institutional investments increasing, and the decrease may stem from mixed analyst ratings and fluctuations in market sentiment, particularly after stock price adjustments by various firms.

Zoetis (ZTS) stock declined by 0

Zoetis Inc. (ZTS) stock experienced a decline of 0.46% due in part to insider selling and adjustments in institutional holdings, with several major investors increasing or decreasing their stakes in the company.

ZTS

Latest News & Analysis